HISTORY OF OUTCOME MEASURES FOR MYASTHENIA GRAVIS

被引：41
作者：
Burns, Ted M. [1 ]
机构：
[1] Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA
来源：
MUSCLE & NERVE | 2010年 / 42卷 / 01期
关键词：
myasthenia gravis; outcome measures; MG Composite; MG-QOL15; rating scales; QUALITY-OF-LIFE; SELF-ADMINISTERED QUESTIONNAIRE; ALTERNATE-DAY PREDNISONE; LONG-TERM CORRELATION; MYCOPHENOLATE-MOFETIL; DOUBLE-BLIND; INTRAVENOUS IMMUNOGLOBULIN; ACETYLCHOLINE-RECEPTORS; RANDOMIZED-TRIAL; CLINICAL-TRIAL;
D O I：
10.1002/mus.21713
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
This review illustrates how measurements of clinical status in patients with myasthenia gravis have evolved from clinical descriptions and estimates of mortality rates to more sophisticated evaluative instruments, including numerical rating scales that measure strength, endurance, quality of life, and activities of daily living. The rationale and use of weighting and the importance of patient-reported outcomes are also discussed. The measurement of the steroid-sparing effect of an immunosuppressant is also reviewed. Muscle Nerve 42: 5-13, 2010
引用
收藏
页码：5 / 13
页数：9
相关论文
共 94 条
[21]   Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases [J].
Chaudhry, V ;
Cornblath, DR ;
Griffin, JW ;
O'Brien, R ;
Drachman, DB .
NEUROLOGY, 2001, 56 (01) :94-96
[22]   Mycophenolate mofetil for myasthenia gravis: An open-label pilot study [J].
Ciafaloni, E ;
Massey, JM ;
Tucker-Lipscomb, B ;
Sanders, DB .
NEUROLOGY, 2001, 56 (01) :97-99
[23]   FUNCTIONAL ACTIVITIES OF AUTOANTIBODIES TO ACETYLCHOLINE-RECEPTORS AND THE CLINICAL SEVERITY OF MYASTHENIA-GRAVIS [J].
DRACHMAN, DB ;
ADAMS, RN ;
JOSIFEK, LF ;
SELF, SG .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (13) :769-775
[24]   PRESENT STATUS OF THYMECTOMY IN TREATMENT OF MYASTHENIA GRAVIS [J].
EATON, LM ;
CLAGETT, OT .
AMERICAN JOURNAL OF MEDICINE, 1955, 19 (05) :703-717
[25]   THYMECTOMY IN THE TREATMENT OF MYASTHENIA GRAVIS - RESULTS IN 72 CASES COMPARED WITH 142 CONTROL CASES [J].
EATON, LM ;
CLAGETT, OT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1950, 142 (13) :963-967
[26]  
Erb W., 1879, ARCH PSYCHIAT, V9, P325
[27]   MRI and clinical studies of facial and bulbar muscle involvement in MUSK antibody-associated myasthenia gravis [J].
Farrugia, Maria Elena ;
Robson, Matthew D. ;
Clover, Linda ;
Anslow, Phil ;
Newsom-Davis, John ;
Kennett, Robin ;
Hilton-Jones, David ;
Matthews, Paul M. ;
Vincent, Angela .
BRAIN, 2006, 129 :1481-1492
[28]   PLACE OF CORTICOTROPIN IN THE TREATMENT OF MYASTHENIA GRAVIS [J].
FREYDBERG, LD .
ANNALS OF INTERNAL MEDICINE, 1960, 52 (04) :806-818
[29]   Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis [J].
Gajdos, P ;
Chevret, S ;
Clair, B ;
Tranchant, C ;
Chastang, C .
ANNALS OF NEUROLOGY, 1997, 41 (06) :789-796
[30]   Standards of measurements in myasthenia gravis [J].
Gajdos, P ;
Sharshar, T ;
Chevret, S .
MYASTHENIA GRAVIS AND RELATED DISORDERS: BIOMCHEMICAL BASIS FOR DISEASE OF THE NEUROMUSCULAR JUNCTION, 2003, 998 :445-452
12345678910